In this regard, the MAL (myelin and lymphocyte protein) gene, implicated in conferring resistance to cancer therapy, is differentially upregulated in short-term survivors (three-fold increase compared with long-term survivors and 29-fold increase compared with early-stage patients) [74]. Here, MAL is linked to cancer.